CB Insights Selects Three of Legend Capital's Portfolio Companies as “2022 China's Active Biocomputing Companies under The Era of Digital Economy”

Under the dual background of China's full entry into the digital economy era and the country's promotion of the bioeconomy as a new engine for economic development, CB Insights China focuses on biocomputing and pays attention to biocomputing companies in China. With prerequisites for being in China, relying on Chinese resources, and serving China, CB Insights selects 18 active biocomputing companies based on the dimensions of enterprise technological innovation, pipeline advancement, project cooperation, investment, financing, etc., which three of them, BioMap, StoneWise, and Xbiome, are portfolio companies of Legend Capital.

BioMap Keywords: innovative drug R&D platform driven by biological computing engine

Based on the high-dimensional multi-omics, high-throughput wet experiment, and biological supercomputing platform, a high-throughput dry-wet closed-loop biological computing engine is constructed to accelerate the discovery of complex disease mechanisms and improve the efficiency of life science R&D. At present, it has 50+ targets and a portfolio of drug R&D assets covering more than 10 immune-related diseases, including tumor immunity, autoimmune diseases, fibrotic diseases, and aging-related diseases.

StoneWise Keywords: molecular design platform + underlying theoretical breakthrough

By utilizing the extensive industry experience in drug R&D, innovative data integration methods, and robust software and engineering capabilities, StoneWise has built an integrated technology platform centered on target pocket research, molecule generation, ultra-high-throughput virtual screening, rational design, and druggability optimization, to improve the efficiency and success rate of multiple key links in the process of new drug R&D from the hit discovery to the preclinical candidate compound process.

Xbiome Keywords: three AI+ microecological drug pipelines enter the clinical stage

Xbiome is an AI+ innovative therapy pioneer in microecological drug R&D and possesses an advanced and complete microecological drug R&D platform. On the AI side, it has a computing platform, an algorithm analysis platform, and a drug discovery platform. On the BT side, Xbiome builds a high-throughput automated experiment platform, an animal model validation platform, and a production and clinical platform. Xbiome owns more than 10 drug pipelines, covering tumors, neurological diseases, digestive and metabolic diseases, and immune-related diseases. A total of 3 drug pipelines enter the clinical stage in 2021-2022.